Dynacure taps U.S. crossovers in €50M series C to fund orphan muscle disease studies

Dynacure expects its €50 million ($55.4 million) series C round to fund an ongoing trial of its lead program for myotubular and centronuclear myopathies in adults, as well as a planned pediatric study. Together, the trials could point the way to a pivotal trial in about two years -- and could be what sells investors on a potential IPO.

Dynacure S.A.S.’s round includes two new U.S.-based investors: Perceptive Advisors, which led the financing, and Tekla Capital Management. Also participating were new investor Bpifrance Large Venture and existing investors Andera Partners, two additional Bpifrance funds, founding investor Kurma Partners and Pontifax...